Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ciprofloxacin + anthrax vaccine adsorbed
- Development stage
- Phase 2
- Lead developer
- Emergent BioSolutions
- Modality
- Vaccines & Immunotherapeutics, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
**ciprofloxacin + anthrax vaccine adsorbed** is a combination therapy used as post-exposure prophylaxis against inhalational anthrax. Ciprofloxacin is a broad-spectrum fluoroquinolone antibiotic that targets bacterial DNA gyrase and topoisomerase IV, inhibiting bacterial DNA replication and cell division. Anthrax vaccine adsorbed (AVA, marketed as BioThrax) is an inactivated bacterial vaccine inducing active immunity against *Bacillus anthracis* by stimulating production of neutralizing antibodies to protective antigen. This dual regimen provides immediate antimicrobial action via ciprofloxacin to control the vegetative form of anthrax, while AVA induces active, long-lasting immune protection against spores that may germinate after antibiotic therapy ends. The combination has demonstrated no significant pharmacokinetic interactions or negative effects on vaccine immunogenicity, and is used especially in situations of known or suspected exposure to anthrax, including bioterrorism emergencies[1][3][4].
- Other names
- ciprofloxacin + AVAciprofloxacin + BioThrax
02
Targets
PA (Influenza polymerase acidic protein)DNA gyraseTopo IV (Bacterial Topoisomerase IV)
Beyond the preview
Go deeper on ciprofloxacin + anthrax vaccine adsorbed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ciprofloxacin + anthrax vaccine adsorbed.